Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 767

1.

Identification of Restless Legs Syndrome Genes by Mutational Load Analysis.

Tilch E, Schormair B, Zhao C, Salminen AV, Antic Nikolic A, Holzknecht E, Högl B, Poewe W, Bachmann CG, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Fietze I, Berger K, Lichtner P, Gieger C, Peters A, Müller-Myhsok B, Hoischen A, Winkelmann J, Oexle K.

Ann Neurol. 2019 Dec 1. doi: 10.1002/ana.25658. [Epub ahead of print]

PMID:
31788832
2.

Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons.

Ganjam GK, Bolte K, Matschke LA, Neitemeier S, Dolga AM, Höllerhage M, Höglinger GU, Adamczyk A, Decher N, Oertel WH, Culmsee C.

Cell Death Dis. 2019 Nov 14;10(11):865. doi: 10.1038/s41419-019-2091-2.

3.

Reduced central sympathetic activity in Parkinson's disease.

Krämer HH, Lautenschläger G, de Azevedo M, Doppler K, Schänzer A, Best C, Oertel WH, Reuter I, Sommer C, Birklein F.

Brain Behav. 2019 Dec;9(12):e01463. doi: 10.1002/brb3.1463. Epub 2019 Nov 5.

4.

Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse.

Schweyer K, Rüschoff-Steiner C, Arias-Carrión O, Oertel WH, Rösler TW, Höglinger GU.

Sci Rep. 2019 Sep 16;9(1):13359. doi: 10.1038/s41598-019-49920-5.

5.

Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Wong YC, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, Trudeau LE, Yue Z, Krainc D, Oertel W, Obeso JA, Volpicelli-Daley LA.

Mov Disord. 2019 Oct;34(10):1406-1422. doi: 10.1002/mds.27823. Epub 2019 Sep 4. Review.

PMID:
31483900
6.

Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko D; PPMI study.

Mov Disord. 2019 Sep;34(9):1354-1364. doi: 10.1002/mds.27806. Epub 2019 Jul 30.

PMID:
31361367
7.

The locus coeruleus: Another vulnerability target in Parkinson's disease.

Oertel WH, Henrich MT, Janzen A, Geibl FF.

Mov Disord. 2019 Oct;34(10):1423-1429. doi: 10.1002/mds.27785. Epub 2019 Jul 10. No abstract available.

PMID:
31291485
8.

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU; PROMESA Study Group.

Lancet Neurol. 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3. Epub 2019 Jul 2.

PMID:
31278067
9.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Aug;34(8):1228-1232. doi: 10.1002/mds.27666. Epub 2019 Mar 18.

10.

Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.

Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung KY, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon JF, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A.

Brain. 2019 Mar 1;142(3):744-759. doi: 10.1093/brain/awz030.

11.

Development of evidence-based quality indicators for deep brain stimulation in patients with Parkinson's disease and first year experience of implementation of a nation-wide registry.

Haas K, Stangl S, Steigerwald F, Matthies C, Gruber D, Kühn AA, Krauss JK, Sixel-Döring F, von Eckardstein K, Deuschl G, Classen J, Winkler D, Voges J, Galazky I, Oertel W, Ceballos-Baumann AO, Lange M, Gharabaghi A, Weiss DT, Volkmann J, Heuschmann PU.

Parkinsonism Relat Disord. 2019 Mar;60:3-9. doi: 10.1016/j.parkreldis.2019.01.016. Epub 2019 Feb 5.

PMID:
30772278
12.

Abnormal α-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility.

Donadio V, Doppler K, Incensi A, Kuzkina A, Janzen A, Mayer G, Volkmann J, Rizzo G, Antelmi E, Plazzi G, Sommer C, Liguori R, Oertel WH.

Eur J Neurol. 2019 Oct;26(10):1245-1251. doi: 10.1111/ene.13939. Epub 2019 Aug 2.

PMID:
30770596
13.

Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson's Disease.

Arnaldi D, Meles SK, Giuliani A, Morbelli S, Renken RJ, Janzen A, Mayer G, Jonsson C, Oertel WH, Nobili F, Leenders KL, Pagani M; REMPET Study Group.

J Parkinsons Dis. 2019;9(1):229-239. doi: 10.3233/JPD-181468.

PMID:
30741687
14.

Widespread microglial activation in multiple system atrophy.

Kübler D, Wächter T, Cabanel N, Su Z, Turkheimer FE, Dodel R, Brooks DJ, Oertel WH, Gerhard A.

Mov Disord. 2019 Apr;34(4):564-568. doi: 10.1002/mds.27620. Epub 2019 Feb 6.

15.

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder.

Chahine LM, Iranzo A, Fernández-Arcos A, Simuni T, Seedorff N, Caspell-Garcia C, Amara AW, Comella C, Högl B, Hamilton J, Marek K, Mayer G, Mollenhauer B, Postuma R, Tolosa E, Trenkwalder C, Videnovic A, Oertel W; PPMI Sleep Working Group.

NPJ Parkinsons Dis. 2019 Jan 29;5:2. doi: 10.1038/s41531-018-0073-1. eCollection 2019.

16.

Reply to: A note on rotigotine for restless legs syndrome after renal transplantation.

Salminen AV, Allen RP, Högl B, Inoue Y, Oertel W, Winkelman JW, Trenkwalder C, Sampaio C, Winkelmann J.

Mov Disord. 2019 Jan;34(1):152-153. doi: 10.1002/mds.27570. No abstract available.

PMID:
30653726
17.

Reply to: Safety of dopamine agonists for treating restless legs syndrome.

Salminen AV, Allen RP, Högl B, Inoue Y, Oertel W, Winkelman JW, Trenkwalder C, Sampaio C, Winkelmann J.

Mov Disord. 2019 Jan;34(1):150-151. doi: 10.1002/mds.27571. No abstract available.

PMID:
30653723
18.

Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Geibl FF, Henrich MT, Oertel WH.

J Neural Transm (Vienna). 2019 Apr;126(4):377-396. doi: 10.1007/s00702-019-01970-9. Epub 2019 Jan 14. Review.

PMID:
30643975
19.

Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene.

Doppler K, Brockmann K, Sedghi A, Wurster I, Volkmann J, Oertel WH, Sommer C.

Front Neurol. 2018 Dec 17;9:1094. doi: 10.3389/fneur.2018.01094. eCollection 2018.

20.

Validation of a new data-driven automated algorithm for muscular activity detection in REM sleep behavior disorder.

Cesari M, Christensen JAE, Sixel-Döring F, Trenkwalder C, Mayer G, Oertel WH, Jennum P, Sorensen HBD.

J Neurosci Methods. 2019 Jan 15;312:53-64. doi: 10.1016/j.jneumeth.2018.11.016. Epub 2018 Nov 20.

PMID:
30468824
21.

A punch in the gut - Intestinal inflammation links environmental factors to neurodegeneration in Parkinson's disease.

Becker A, Faßbender K, Oertel WH, Unger MM.

Parkinsonism Relat Disord. 2019 Mar;60:43-45. doi: 10.1016/j.parkreldis.2018.09.032. Epub 2018 Sep 29.

PMID:
30292735
22.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
23.

Comparison of computerized methods for rapid eye movement sleep without atonia detection.

Cesari M, Christensen JAE, Kempfner L, Olesen AN, Mayer G, Kesper K, Oertel WH, Sixel-Döring F, Trenkwalder C, Sorensen HBD, Jennum P.

Sleep. 2018 Oct 1;41(10). doi: 10.1093/sleep/zsy133.

PMID:
30011023
24.

Towards earlier diagnosis and treatment of disorders of the brain.

Di Luca M, Nutt D, Oertel W, Boyer P, Jaarsma J, Destrebecq F, Esposito G, Quoidbach V.

Bull World Health Organ. 2018 May 1;96(5):298-298A. doi: 10.2471/BLT.17.206599. No abstract available.

25.

Validation of semiautomatic scoring of REM sleep without atonia in patients with RBD.

Guttowski D, Mayer G, Oertel WH, Kesper K, Rosenberg T.

Sleep Med. 2018 Jun;46:107-113. doi: 10.1016/j.sleep.2018.03.010. Epub 2018 Mar 31.

PMID:
29773203
26.

Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§.

Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, Winkelman JW, Trenkwalder C, Sampaio C.

Mov Disord. 2018 Jul;33(7):1077-1091. doi: 10.1002/mds.27260. Epub 2018 May 14. Review.

PMID:
29756335
27.

A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.

Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH.

Acta Neuropathol Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1.

28.

LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder.

Ouled Amar Bencheikh B, Ruskey JA, Arnulf I, Dauvilliers Y, Monaca CC, De Cock VC, Gagnon JF, Spiegelman D, Hu MTM, Högl B, Stefani A, Ferini-Strambi L, Plazzi G, Antelmi E, Young P, Heidbreder A, Mollenhauer B, Sixel-Döring F, Trenkwalder C, Oertel W, Montplaisir JY, Postuma RB, Rouleau GA, Gan-Or Z.

Parkinsonism Relat Disord. 2018 Jul;52:98-101. doi: 10.1016/j.parkreldis.2018.03.019. Epub 2018 Mar 21.

PMID:
29576439
29.

Calcium-activated SK potassium channels are key modulators of the pacemaker frequency in locus coeruleus neurons.

Matschke LA, Rinné S, Snutch TP, Oertel WH, Dolga AM, Decher N.

Mol Cell Neurosci. 2018 Apr;88:330-341. doi: 10.1016/j.mcn.2018.03.002. Epub 2018 Mar 8.

PMID:
29524627
30.

The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease.

Meles SK, Renken RJ, Janzen A, Vadasz D, Pagani M, Arnaldi D, Morbelli S, Nobili F, Mayer G, Leenders KL, Oertel WH; REMPET Study Group.

J Nucl Med. 2018 Sep;59(9):1437-1444. doi: 10.2967/jnumed.117.202242. Epub 2018 Feb 23.

31.

The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?

Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F.

Parkinsonism Relat Disord. 2018 Jun;51:9-16. doi: 10.1016/j.parkreldis.2018.02.001. Epub 2018 Feb 2. Review.

PMID:
29456046
32.

Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.

Müller-Rebstein S, Trenkwalder C, Ebentheuer J, Oertel WH, Culmsee C, Höglinger GU.

CNS Drugs. 2017 Dec;31(12):1093-1102. doi: 10.1007/s40263-017-0478-0.

PMID:
29139041
33.

Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.

Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Pütz B, Dauvilliers Y, Stefani A, Högl B, Poewe W, Kemlink D, Sonka K, Bachmann CG, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Teder-Laving M, Metspalu A, Hadjigeorgiou GM, Polo O, Fietze I, Ross OA, Wszolek Z, Butterworth AS, Soranzo N, Ouwehand WH, Roberts DJ, Danesh J, Allen RP, Earley CJ, Ondo WG, Xiong L, Montplaisir J, Gan-Or Z, Perola M, Vodicka P, Dina C, Franke A, Tittmann L, Stewart AFR, Shah SH, Gieger C, Peters A, Rouleau GA, Berger K, Oexle K, Di Angelantonio E, Hinds DA, Müller-Myhsok B, Winkelmann J; 23andMe Research Team; DESIR study group.

Lancet Neurol. 2017 Nov;16(11):898-907. doi: 10.1016/S1474-4422(17)30327-7. Review.

34.

Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons.

Wagner J, Vulinović F, Grünewald A, Unger MM, Möller JC, Klein C, Michel PP, Ries V, Oertel WH, Alvarez-Fischer D.

Neuroscience. 2017 Dec 4;365:137-145. doi: 10.1016/j.neuroscience.2017.09.045. Epub 2017 Oct 4.

PMID:
28987508
35.

Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.

Höllerhage M, Moebius C, Melms J, Chiu WH, Goebel JN, Chakroun T, Koeglsperger T, Oertel WH, Rösler TW, Bickle M, Höglinger GU.

Sci Rep. 2017 Sep 13;7(1):11469. doi: 10.1038/s41598-017-11664-5.

36.

The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.

Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B, Wilmes P.

Mov Disord. 2018 Jan;33(1):88-98. doi: 10.1002/mds.27105. Epub 2017 Aug 26.

37.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.

Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.

38.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.

Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ.

J Parkinsons Dis. 2017;7(3):511-522. doi: 10.3233/JPD-171134.

39.

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.

Meles SK, Vadasz D, Renken RJ, Sittig-Wiegand E, Mayer G, Depboylu C, Reetz K, Overeem S, Pijpers A, Reesink FE, van Laar T, Heinen L, Teune LK, Höffken H, Luster M, Kesper K, Adriaanse SM, Booij J, Leenders KL, Oertel WH.

Mov Disord. 2017 Oct;32(10):1482-1486. doi: 10.1002/mds.27094. Epub 2017 Jul 22.

40.

Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.

Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A; FCM-RLS Study Investigators.

Mov Disord. 2017 Oct;32(10):1478-1482. doi: 10.1002/mds.27040. Epub 2017 Jun 23.

41.

Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease.

Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, Simuni T; Parkinson’s Progression Markers Initiative.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):653-662. doi: 10.1136/jnnp-2016-315023. Epub 2017 May 29.

PMID:
28554959
42.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13. Review.

43.

[Pharmacotherapy of Parkinson's disease : Aspects of drug safety].

Müller-Rebstein S, Trenkwalder C, Oertel WH, Culmsee C, Eckermann G, Höglinger GU.

Nervenarzt. 2017 Aug;88(8):888-894. doi: 10.1007/s00115-017-0345-8. Review. German.

PMID:
28497256
44.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

45.

Recent advances in treating Parkinson's disease.

Oertel WH.

F1000Res. 2017 Mar 13;6:260. doi: 10.12688/f1000research.10100.1. eCollection 2017. Review.

46.

Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.

Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH.

Acta Neuropathol. 2017 Apr;133(4):535-545. doi: 10.1007/s00401-017-1684-z. Epub 2017 Feb 8.

47.

Manual MRI morphometry in Parkinsonian syndromes.

Möller L, Kassubek J, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Pinkhardt EH, Respondek G, Stamelou M, Möller F, Schnitzler A, Oertel WH, Knake S, Huppertz HJ, Höglinger GU.

Mov Disord. 2017 May;32(5):778-782. doi: 10.1002/mds.26921. Epub 2017 Feb 2.

PMID:
28150443
48.

Is increased spinal nociception another hallmark for Parkinson's disease?

Boura E, Stamelou M, Vadasz D, Ries V, Unger MM, Kägi G, Oertel WH, Möller JC, Mylius V.

J Neurol. 2017 Mar;264(3):570-575. doi: 10.1007/s00415-016-8390-y. Epub 2017 Jan 24.

PMID:
28120040
49.

Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.

Lahut S, Gispert S, Ömür Ö, Depboylu C, Seidel K, Domínguez-Bautista JA, Brehm N, Tireli H, Hackmann K, Pirkevi C, Leube B, Ries V, Reim K, Brose N, den Dunnen WF, Johnson M, Wolf Z, Schindewolf M, Schrempf W, Reetz K, Young P, Vadasz D, Frangakis AS, Schröck E, Steinmetz H, Jendrach M, Rüb U, Başak AN, Oertel W, Auburger G.

Dis Model Mech. 2017 May 1;10(5):619-631. doi: 10.1242/dmm.028035. Epub 2017 Jan 20.

50.

Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.

Lasser-Katz E, Simchovitz A, Chiu WH, Oertel WH, Sharon R, Soreq H, Roeper J, Goldberg JA.

J Neurosci. 2017 Jan 4;37(1):47-57. doi: 10.1523/JNEUROSCI.1079-16.2016.

Supplemental Content

Loading ...
Support Center